Autolus Therapeutics plc ADR
Autolus Therapeutics plc ADR (AUTL) Historical Volatility
AUTL's 30 day historical volatility is 58.00%, in the 14th percentile of readings over the past year. This is a low percentile, meaning Autolus Therapeutics plc ADR shares have been calmer than usual. AUTL's 30 day implied volatility sits at 498.56%, with an IV Rank of 99.60%, leaving IV 440.56 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 18, 2026.
Read more
Tracking AUTL historical volatility helps you see how much Autolus Therapeutics plc ADR's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, AUTL's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor AUTL 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. AUTL's 30 day historical volatility, or AUTL HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing AUTL's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.
Historical Volatility
Historical movement is subdued versus the past year. The stock has been unusually quiet.
As of Nov 18, 2026
As of Nov 18, 2026
As of Nov 18, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →